How Mochi Health Compares to the Standard of Care The American Association of Clinical Endocrinology (AACE) 2023 obesity management algorithm recommends that patients with BMI 30 (or BMI 27 with at least one obesity-related comorbidity) be offered pharmacotherapy alongside lifestyle intervention, with prescriber follow-up at 4, 8, and 12 weeks after initiation, then every 3 months [13]
Every plan comes with: A licensed clinician review and a written prescription Compounded semaglutide or tirzepatide, available as an injection or oral gum Supplies needed for injectable administration Free expedited shipping through FedEx or UPS Access to the Embody patient portal 24/7 messaging support with your care team Dosage review and adjustment at each refill New patients also get a personalized metabolic report and a one-on-one guidance session with a provider during the first month, giving them a clinical starting point before treatment begins
Learn more about our semaglutide weight loss program and tirzepatide weight loss program
Many individuals choose IV hydration as part of a wellness routine to help support hydration and nutrient intake
For Canadians researching peptide options, Retatrutide offers several advantages beyond raw efficacy
Here's a referral for a colonoscopy that comes back clean